Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma.

about

Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma.

Item

http://www.wikidata.org/entity/Q41275180

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Are All Mutations the Same? A ...... tastatic Colon Adenocarcinoma.

@en

type

Item

label

Are All Mutations the Same? A ...... tastatic Colon Adenocarcinoma.

@en

prefLabel

Are All Mutations the Same? A ...... tastatic Colon Adenocarcinoma.

@en

P1476

Are All Mutations the Same? A ...... tastatic Colon Adenocarcinoma.

@en

P2093

Akshay Middinti

http://www.w3.org/2001/XMLSchema#string

Anusha Vittal

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

Cancer statistics, 2016

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color

KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.

Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature.

Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.

Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.

P304

2321052

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1155/2017/2321052

http://www.w3.org/2001/XMLSchema#string

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

Anup Kasi

P577

2017-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28811946

http://www.w3.org/2001/XMLSchema#string

P932

5546060

http://www.w3.org/2001/XMLSchema#string